Anticancer Drugs: Recent Advances and Challenges
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 574
Special Issue Editors
Interests: cancer vaccines; immunotherapy; cell therapy; small molecules; high-throughput screening
Special Issue Information
Dear Colleagues,
Technical advances in cell culture, robotics, computational biology, and development of reporter systems have transformed the field of drug discovery, enabling improved screening approaches for novel anticancer treatments. However, the translation of anticancer compounds identified in vitro into clinically active drugs has a limited success rate. The objective of the current Special Issue is to highlight success stories and/or novel processes of phenotype-based high-throughput drug screening in targeting malignant cells. Submission of studies describing computational approaches linking transcriptomic profiling of cancers with existing pharmaceutical compounds to accelerate drug repurposing or the use of CRISPR-based screening for the discovery of mechanisms of drug resistance and sensitization are strongly encouraged.
Dr. Moutih Rafei
Dr. Sebastien Talbot
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multi-omics
- high-throughput screening
- anticancer compounds
- CRISPR
- drug repurposing
- cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
